Oculis Holding AG (NASDAQ:OCSAW – Get Free Report) saw a significant increase in short interest in June. As of June 15th, there was short interest totaling 7,902 shares, an increase of 395,000.0% from the May 31st total of 2 shares. Based on an average daily volume of 22,128 shares, the days-to-cover ratio is presently 0.4 days.
Oculis Stock Performance
OCSAW stock opened at $4.22 on Friday. The business’s 50-day moving average price is $12.58 and its two-hundred day moving average price is $13.45. Oculis has a 1-year low of $3.63 and a 1-year high of $22.64.
Oculis Company Profile
Oculis SA is a clinical‐stage biopharmaceutical company focused on developing disease‐modifying therapies for serious eye diseases. Utilizing its proprietary ocular formulation technologies, the company is advancing a pipeline of small‐molecule product candidates designed for topical or injectable delivery. Lead programs include OCS-01, a topical eye drop candidate for diabetic macular edema, and OCS-02, targeting diabetic retinopathy. Oculis also has OCS-05 in development for optic neuropathies and other retinal disorders, reflecting its commitment to addressing a broad spectrum of unmet needs in ophthalmology.
Founded in 2016 and headquartered in Geneva, Switzerland, Oculis operates research and development facilities in Europe and the United States.
Featured Articles
- Five stocks we like better than Oculis
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
